Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHILITH vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 14 years old who have no known contraindications to oral contraceptive therapy and have achieved menarche,Treatment of premenstrual dysphoric disorder (PMDD) in women of reproductive age
Prevention of pregnancy
1 mg orally once daily
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol is metabolized primarily by CYP3A4, with sulfation and glucuronidation; drospirenone is metabolized by CYP3A4.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
98% bound to albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.3 L/kg; suggests limited extravascular distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 80% (high first-pass metabolism).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 0.5 mg once daily; GFR <15 m L/min: not recommended
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg once daily; Child-Pugh C: not recommended
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not approved for use in children under 18 years
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No specific adjustment; monitor renal function and adjust per renal guidelines
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thromboembolic and thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction) especially in smokers over 35,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolic effects,Hepatic neoplasia risk,Increased risk of pancreatitis due to hypertriglyceridemia,Chloasma (melasma) possibly persistent,Hereditary angioedema exacerbation in women with C1 esterase inhibitor deficiency,Impaired liver function
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Pregnancy,Current or history of thrombophlebitis or venous thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Hepatic adenoma or carcinoma,Jaundice or cholestatic jaundice of pregnancy or prior pill use,Known hypersensitivity to any component,Smoking over age 35,Uncontrolled hypertension,Diabetes with vascular involvement,Migraine with focal aura,Severe renal insufficiency or adrenal insufficiency (due to drospirenone's antimineralocorticoid effect)
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Grapefruit and grapefruit juice may increase estrogen levels, leading to increased side effects. St. John's Wort may decrease contraceptive effectiveness. Avoid excessive alcohol consumption as it may increase liver enzyme induction and reduce efficacy.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
PHILITH is contraindicated in pregnancy. First trimester exposure carries high risk of neural tube defects, cardiac anomalies, and cleft palate based on animal studies and limited human data. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal renal impairment.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
It is unknown whether PHILITH is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy and for 2 weeks after last dose. M/P ratio is not available.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
PHILITH is contraindicated in pregnancy; no dose adjustment can be recommended. Physiologic increases in renal clearance and hepatic metabolism during pregnancy may reduce drug exposure, but the teratogenic risk precludes use. If inadvertent exposure occurs, immediately discontinue and consider alternative therapy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
PHILITH is a combination oral contraceptive containing ethinyl estradiol and progestin. Monitor for thromboembolic events; avoid in smokers over 35. Start on first day of menses or first Sunday after onset. Missed dose management: if missed >48 hours, use backup contraception for 7 days.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at same time; missed pills increase pregnancy risk.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Use backup contraception (e.g., condoms) if you miss two or more pills.,Contact healthcare provider if you experience leg pain, chest pain, shortness of breath, or severe headache.,The medication does not protect against sexually transmitted infections.,You may have spotting or nausea initially; these usually improve.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHILITH vs ALYACEN 7/7/7, answered by our medical review team.
PHILITH is a Oral Contraceptive that works by PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHILITH and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHILITH is: 1 mg orally once daily. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHILITH and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHILITH is classified as Category C. PHILITH is contraindicated in pregnancy. First trimester exposure carries high risk of neural tube defects, cardiac anomalies, and cleft palate based on animal studies and limited . ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.